Characterization of Predictors of Response or Resistance to ICIs in NSCLC
PD-L1 expression density and cytotoxic T cells were identified as potential biomarkers for outcomes with ICIs in patients with NSCLC.
European Society for Medical Oncology (ESMO)
Apatinib Plus Gefitinib Improved PFS in EGFR-Mutated NSCLC
The addition of apatinib to gefitinib prolonged PFS compared with gefitinib among treatment-naive patients with EGFR-mutated NSCLC.
No Benefit, Higher Toxicities With Postoperative Conformal RT in Stage IIIAN2 NSCLC
The use of modern postoperative conformal radiotherapy did not improve DFS and was associated with toxicities among patients with stage IIIAN2 NSCLC.
Longitudinal NGS May Identify Patients At Risk for Hyperprogression or Death From ICIs
NGS of longitudinal samples from patients with advanced NSCLC receiving ICIs identified changes associated with hyperprogression and early death.
KRAS Inhibitor Shows Favorable Activity in Advanced NSCLC
Results from a phase 1 trial suggest a KRASG12C inhibitor has a favorable safety profile and antitumor activity in advanced NSCLC.
Characteristics and Treatment Patterns of KRASG12C-Mutated NSCLC
An analysis of from the Flatiron Health Network found that some patients with NSCLC with a KRASG12C mutation do not receive systemic therapy.
Gene Signatures are Potential Biomarkers for ccRCC
Several gene signatures were associated with outcomes among patients with advanced clear cell RCC, but not non-clear cell RCC.
Gene Expression Signatures May be Predictive for Nivolumab in ccRCC
Gene signatures were identified as potential predictive biomarkers for outcomes with nivolumab among patients with advanced ccRCC in an analysis of the NIVOREN GETUG-AFU 26 trial.
ctDNA Concordant with Tissue Genomic Analysis in RCC
Circulating tumor DNA analysis of genomic alterations was concordant with tissue genomic analysis in a cohort of patients with advanced RCC.
Atezolizumab Plus Cabozantinib Shows Promising Early Results in ccRCC
Atezolizumab plus cabozantinib was tolerable and demonstrated antitumor activity in patients with treatment-naïve, advanced ccRCC, according to a phase 1b study.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO Virtual Congress 2020 RCC In-depth
